Cochrane at the WHO Executive Board 2024

Last week, Cochrane participated in the154th session of the World Health Organization (WHO) Executive Board meeting in Geneva.The Executive Board is composed of 34 technically qualified representatives from different Member States, elected for three-year terms. Every January, the Executive Board meets at WHO headquarters to discuss global public health priorities for the year ahead and set the agenda for theWorld Health Assembly.In addition to the Executive Board, all Member States and civil society organizations in official relations with WHO, such as Cochrane, are given the opportunity to contribute. This provided our delegation a great platform to advocate for evidence-based health policy.  The session began with an opening statement by WHO Director-General. He highlighted the key achievements of the previous year, including the landmark decision to include life-changing treatments for multiple sclerosis drugs in the Essential Medicines List, whichCochrane Multiple Sclerosis and Rare Diseases of the CNS played a key role in.WHO ’s 14th General Programme of Work (GPW14) was a major focus of this year ’s meeting. GPW14 is a medium-term strategy agreed by Member States and will defines the direction of WHO’s work (including on evidence-based health) for 2025-28, with the goal to promote, provide, and protect health. Emma Thompson, Cochrane ’s Advocacy and Partnerships Lead, made a statement in front of Member States and WHO’s Director-General, speaking on behalf o...
Source: Cochrane News and Events - Category: Information Technology Authors: Source Type: news